SES AI Reports Q4 Results, Shares Volatile

SES AI Corporation (NYSE:SES) is a company involved in the development and commercialization of advanced battery technologies. The company focuses on creating high-performance lithium-metal batteries, which are crucial for electric vehicles and other energy storage applications. In the competitive landscape, SES faces peers like Solid Power, Inc. and Yield10 Bioscience, Inc., each with varying degrees of capital efficiency.

SES AI Corporation's financial metrics reveal a challenging situation. With a Return on Invested Capital (ROIC) of -35.23% and a Weighted Average Cost of Capital (WACC) of 5.30%, SES is not generating returns above its cost of capital. This negative ROIC indicates inefficiencies in how SES utilizes its capital, which could impact its long-term financial health.

In comparison, BIMI International Medical Inc. shows an even more concerning ROIC of -118.77% against a WACC of 62.74%. This results in a ROIC to WACC ratio of -1.89, highlighting severe inefficiencies. Similarly, Viveve Medical, Inc. has a ROIC of -100.93% and a WACC of 18.60%, leading to a ratio of -5.43, indicating poor capital utilization.

On the other hand, Yield10 Bioscience, Inc. stands out with a ROIC of 243.83% and a WACC of 4.64%, resulting in a ROIC to WACC ratio of 52.55. This suggests that Yield10 is effectively utilizing its capital to generate returns far exceeding its cost, showcasing strong growth potential and efficient capital management.

SES AI Corporation (NYSE:SES) is a company involved in the development and commercialization of advanced battery technologies. The company focuses on creating high-performance lithium-metal batteries, which are crucial for electric vehicles and other energy storage applications. In the competitive landscape, SES faces peers like Solid Power, Inc. and Yield10 Bioscience, Inc., each with varying degrees of capital efficiency.

SES AI Corporation's financial metrics reveal a challenging situation. With a Return on Invested Capital (ROIC) of -35.23% and a Weighted Average Cost of Capital (WACC) of 5.30%, SES is not generating returns above its cost of capital. This negative ROIC indicates inefficiencies in how SES utilizes its capital, which could impact its long-term financial health.

In comparison, BIMI International Medical Inc. shows an even more concerning ROIC of -118.77% against a WACC of 62.74%. This results in a ROIC to WACC ratio of -1.89, highlighting severe inefficiencies. Similarly, Viveve Medical, Inc. has a ROIC of -100.93% and a WACC of 18.60%, leading to a ratio of -5.43, indicating poor capital utilization.

On the other hand, Yield10 Bioscience, Inc. stands out with a ROIC of 243.83% and a WACC of 4.64%, resulting in a ROIC to WACC ratio of 52.55. This suggests that Yield10 is effectively utilizing its capital to generate returns far exceeding its cost, showcasing strong growth potential and efficient capital management.

SES AI Corporation (NYSE:SES) shares jumped nearly 10% on Tuesday after the company reported its Q4 results, however, it was followed by today’s 7% decline in the share price.

The company reported mixed Q4 results and more importantly provided an operational update as it continues to progress with its A-sample cell production and moving toward its target of reaching B-sample production and delivery by mid-year. Having achieved ready-to-use status for its three Asamplelines ahead of schedule last year, the company believes it is now on track to transition to B-sample development with its OEM partners this year.

The company has made meaningful progress in addressing the various quality issues with its A-sample 100Ah cells, and plans to leverage its learnings to enable a smoother ramp process as it enters B-sample development with improved volume, speed, and quality. Overall, the company is progressing on track thus far, and management also reiterated that the current cash in hand is sufficient to take it to commercialization.

SES AI Corporation (NYSE:SES) shares jumped nearly 10% on Tuesday after the company reported its Q4 results, however, it was followed by today’s 7% decline in the share price.

The company reported mixed Q4 results and more importantly provided an operational update as it continues to progress with its A-sample cell production and moving toward its target of reaching B-sample production and delivery by mid-year. Having achieved ready-to-use status for its three Asamplelines ahead of schedule last year, the company believes it is now on track to transition to B-sample development with its OEM partners this year.

The company has made meaningful progress in addressing the various quality issues with its A-sample 100Ah cells, and plans to leverage its learnings to enable a smoother ramp process as it enters B-sample development with improved volume, speed, and quality. Overall, the company is progressing on track thus far, and management also reiterated that the current cash in hand is sufficient to take it to commercialization.